CIP
VYGR icon

Convergence Investment Partners’s Voyager Therapeutics VYGR Stock Holding History

Convergence Investment Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,337
Closed -$92K – 321
2019
Q3 		$92K Buy
5,337
+1,387
+35% +$29.1K 0.03% 289
2019
Q2 		$108K Buy
+3,950
New +$90.4K 0.03% 291

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Convergence Investment Partners's VYGR Position: Q4 2019 in Review

Convergence Investment Partners sold out of Voyager Therapeutics (VYGR) in Q4 2019, closing a stake of 5,337 shares — an estimated $92K sold.

Convergence Investment Partners first reported a position in VYGR in Q2 2019 and held it in 2 quarters. The position peaked at $108K in Q2 2019. 138 funds tracked by Wall St. Rank hold VYGR as of Q4 2019.

  • Convergence Investment Partners reported no remaining Voyager Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 5,337 Voyager Therapeutics shares in Q4 2019, an estimated $92K.
  • Convergence Investment Partners first reported a position in Voyager Therapeutics in Q2 2019 and held it in 2 quarters.
  • Convergence Investment Partners's Voyager Therapeutics position peaked at $108K in Q2 2019.
  • 138 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.